Arbutus Biopharma Corporation (NASDAQ: ABUS): Would You Buy Today? – Marketing Sentinel
Home  »  Top Story   »  Arbutus Biopharma Corporation (NASDAQ: ABUS): Woul...

Arbutus Biopharma Corporation (NASDAQ: ABUS): Would You Buy Today?

In the last trading session, 7.06 million shares of the Arbutus Biopharma Corporation (NASDAQ:ABUS) were traded, and its beta was 2.60. Most recently the company’s share price was $4.14, and it changed around -$0.17 or -3.94% from the last close, which brings the market valuation of the company to $581.59M. ABUS currently trades at a discount to its 52-week high of $6.50, offering almost -57.0% off that amount. The share price’s 52-week low was $2.43, which indicates that the current value has risen by an impressive 41.3% since then. We note from Arbutus Biopharma Corporation’s average daily trading volume that its 10-day average is 47.14 million shares, with the 3-month average coming to 9.51 million.

Arbutus Biopharma Corporation stock received a consensus recommendation rating of an Overweight, based on a mean score of 2.40. If we narrow it down even further, the data shows that 0 out of 5 analysts rate the stock as a Sell; another 0 rate it as Overweight. Among the rest, 2 recommended ABUS as a Hold, whereas 3 deemed it a Buy, and 0 rated it as Underweight. Arbutus Biopharma Corporation is expected to report earnings per share of -$0.24 for the current quarter.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


Arbutus Biopharma Corporation (NASDAQ:ABUS) trade information

Instantly ABUS has showed a red trend with a performance of -3.94% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 4.67 on Friday, 12/10/21 increased the stock’s daily price by 11.35%. The company’s shares are currently up 16.62% year-to-date, but still down -0.24% over the last five days. On the other hand, Arbutus Biopharma Corporation (NASDAQ:ABUS) is 18.97% down in the 30-day period. We can see from the shorts that 2.78 million shares have been sold at a short interest cover period of 0.8 day(s).

The consensus price target as assigned by Wall Street analysts is $6.10, which translates to bulls needing to increase their stock price by 32.13% from its current value. Analyst projections state that ABUS is forecast to be at a low of $4.00 and a high of $9.00. In order for the stock price to hit the forecast high, the stock would need to plunge -117.39% from its current level, while the stock would need to crash 3.38% from its current level to reach the projected low.

Arbutus Biopharma Corporation (ABUS) estimates and forecasts

Arbutus Biopharma Corporation share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have risen 21.76 percent over the past six months and at a 13.00% annual growth rate that is well above the industry average of 7.00%. Moreover, analysts have decided to roll up on their fiscal year 2021 revenue estimates. The rating firms predict that it will gain 11.10% in revenue this quarter, and will report an increase of 4.30% in the next quarter. The year-over-year growth rate is expected to be 38.40%, up from the previous year.

Consensus estimates provided by 5 financial analysts predict the company will bring in an average of $2.38 million in revenue for the current quarter. 5 analysts expect Arbutus Biopharma Corporation to make $2.64 million in revenue for the quarter ending Dec 2021. Forecasts for the next quarter put sales growth at 10.60%.

Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 6.20%.

ABUS Dividends

Arbutus Biopharma Corporation’s next quarterly earnings report is expected to be released around November 01 and November 05.

Arbutus Biopharma Corporation (NASDAQ:ABUS)’s Major holders

Upon looking at major shareholders, it appears that insiders hold 19.15% of Arbutus Biopharma Corporation shares, and 29.80% of them are in the hands of institutional investors. The stock currently has a share float of 36.86%. Arbutus Biopharma Corporation stock is held by 123 institutions, with RTW Investments LP being the largest institutional investor. By Jun 29, 2021, it held 6.03% of the shares, which is about 5.98 million shares worth $18.11 million.

Blackrock Inc., with 5.88% or 5.84 million shares worth $17.68 million as of Jun 29, 2021, holds the second largest percentage of outstanding shares.

>> 7 Top Picks for the Post-Pandemic Economy <<

Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF were the top two Mutual Funds as of Jun 29, 2021. The former held 2.33 million shares worth $7.05 million, making up 2.35% of all outstanding shares. On the other hand, iShares Russell 2000 ETF held roughly 1.79 million shares worth around $6.14 million, which represents about 1.80% of the total shares outstanding.

Leave a Comment

Your email address will not be published.

On Key

Related Posts